Prenoxad is approved in five European countries for treatment of opioid overdose-Martindale Pharma.

Martindale Pharma, UK-based international specialty pharmaceutical company, announced the regulatory approval of Prenoxad Injection in Sweden, Denmark, Ireland, Finland and Estonia following the successful completion of a decentralised procedure (DCP).

Developed by Martindale Pharma, Prenoxad Injection is the world’s first take-home naloxone product, designed for use by non-healthcare professionals to treat opioid overdoses in a community setting. Prenoxad Injection is available in the UK since 2012 and over 85,000 units or kits have been supplied to people who are at risk of opioid related overdose or to their nominated representative.

Comment: Prenoxad Injection is a Prescription Only Medicine (POM) containing a solution of naloxone hydrochloride. It is intended for emergency use for the complete or partial reversal of life-threatening respiratory depression following the administration of natural or synthetic opioids. Naloxone is an 'opioid antagonist' medicine with an excellent safety and efficacy profile following use over more than four decades. Prenoxad Injection is a multidose product and is given by intramuscular injection, the only route of delivery proven to be effective in reversing opioid overdoses in a take-home naloxone programme.